At day 85 (approximately 12 weeks), patients in the low-dose group lost an average of 7.19 percent of their body weight and the high-dose group lost an average of 14.52 percent of their body weight, while the placebo group gained an average of 1.49 percent of their body weight
The study, published in Scientific Reports (Liu et al., 2025), systematically extracted and analyzed adverse drug reactions associated with concomitant administration of GLP-1 RAs and metformin for the first time using FAERS data spanning two decades (20042024), encompassing 48,214 adverse drug reaction reports
Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
GLP-1 medications do not permanently alter metabolism
In search of preventive strategies: novel high-CBD Cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues
however, the definitive effects of exenatide in such patients were still inconclusive [81]
